NRF2 as a Therapeutic Target in Neurodegenerative Diseases

被引:169
|
作者
Brandes, Mikah S. [1 ]
Gray, Nora E. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
来源
ASN NEURO | 2020年 / 12卷
关键词
dementia and neurological disorders; neurodegenerative diseases; bioenergetics; NF-KAPPA-B; INDUCED OXIDATIVE STRESS; ALPHA-LIPOIC ACID; REMITTING MULTIPLE-SCLEROSIS; TRANSCRIPTION FACTOR NRF2; RELEASE DIMETHYL FUMARATE; PLACEBO-CONTROLLED PHASE-3; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; COMPLEX I DEFICIENCY;
D O I
10.1177/1759091419899782
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increased reactive oxygen species production and oxidative stress have been implicated in the pathogenesis of numerous neurodegenerative conditions including among others Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedrich's ataxia, multiple sclerosis, and stroke. The endogenous antioxidant response pathway protects cells from oxidative stress by increasing the expression of cytoprotective enzymes and is regulated by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2). In addition to regulating the expression of antioxidant genes, NRF2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis. This is because mitochondrial dysfunction and neuroinflammation are features of many neurodegenerative diseases as well NRF2 has emerged as a promising therapeutic target. Here, we review evidence for a beneficial role of NRF2 in neurodegenerative conditions and the potential of specific NRF2 activators as therapeutic agents.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Nrf2 as a therapeutic target for rheumatic diseases
    Luisa Ferrandiz, Maria
    Nacher-Juan, Josep
    Jose Alcaraz, Maria
    [J]. BIOCHEMICAL PHARMACOLOGY, 2018, 152 : 338 - 346
  • [2] The Nrf2/ARE Pathway as a Potential Therapeutic Target in Neurodegenerative Disease
    Calkins, Marcus J.
    Johnson, Delinda A.
    Townsend, Jessica A.
    Vargas, Marcelo R.
    Dowell, James A.
    Williamson, Tracy P.
    Kraft, Andrew D.
    Lee, Jong-Min
    Li, Jiang
    Johnson, Jeffrey A.
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2009, 11 (03) : 497 - 508
  • [3] Nrf2-a therapeutic target for the treatment of neurodegenerative diseases
    Johnson, Delinda A.
    Johnson, Jeffrey A.
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2015, 88 : 253 - 267
  • [4] Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases
    Nakagami, Yasuhiro
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016
  • [5] Expression of Nrf2 in neurodegenerative diseases
    Ramsey, Chenere P.
    Glass, Charles A.
    Montgomery, Marshall B.
    Lindl, Kathryn A.
    Ritson, Gillian P.
    Chia, Luis A.
    Hamilton, Ronald L.
    Chu, Charleen T.
    Jordan-Sciutto, Kelly L.
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2007, 66 (01): : 75 - 85
  • [6] Nrf2/ARE Pathway as a Therapeutic Target for the Treatment of Parkinson Diseases
    Artem P. Gureev
    Vasily N. Popov
    [J]. Neurochemical Research, 2019, 44 : 2273 - 2279
  • [7] Nrf2/ARE Pathway as a Therapeutic Target for the Treatment of Parkinson Diseases
    Gureev, Artem P.
    Popov, Vasily N.
    [J]. NEUROCHEMICAL RESEARCH, 2019, 44 (10) : 2273 - 2279
  • [8] Activators of Nrf2 to Counteract Neurodegenerative Diseases
    Amoroso, Rosa
    Maccallini, Cristina
    Bellezza, Ilaria
    [J]. ANTIOXIDANTS, 2023, 12 (03)
  • [9] Nrf2: A promising therapeutic target in bone-related diseases
    Che, Jingmin
    Yang, Xiaoli
    Jin, Zhankui
    Xu, Cuixiang
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
  • [10] NRF2 as an Emerging Therapeutic Target
    Copple, Ian M.
    Dinkova-Kostova, Albena T.
    Kensler, Thomas W.
    Liby, Karen T.
    Wigley, W. Christian
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017, 2017